Pharmaceuticals
9 companies under coverage.
Pharmaceuticals
Viatris Inc (VTRS)
BUY. 12-month probability-weighted target $20 (+20% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
Zoetis Inc (ZTS)
HOLD. 12-month probability-weighted target $75 (+2% vs spot). P/E Multiple explains 79% of Monte Carlo outcome variance.
Jazz Pharmaceuticals PLC (JAZZ)
HOLD. 12-month probability-weighted target $252 (+5% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.
Eli Lilly and Company (LLY)
HOLD. 12-month probability-weighted target $1100 (-2% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
Bristol-Myers Squibb Company (BMY)
SELL. 12-month probability-weighted target $57 (-12% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Johnson & Johnson (JNJ)
SELL. 12-month probability-weighted target $240 (-11% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Elanco Animal Health (ELAN)
HOLD. 12-month probability-weighted target $25 (+3% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.
Pfizer Inc (PFE)
SELL. 12-month probability-weighted target $23 (-16% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
Merck & Company Inc (MRK)
SELL. 12-month probability-weighted target $122 (-18% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.